Benign and malignant apocrine lesions of the breast

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 215-221

  Gerhard, Renê ^a   Costa, José Luis ^a   Schmitt, Fernando ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

androgen; apocrine; breast; carcinoma; histological subtype

Indexed keywords

ANDROGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN GCDFP 15; TUMOR MARKER; UNCLASSIFIED DRUG;

APOCRINE ADENOSIS; APOCRINE CARCINOMA; ATYPICAL APOCRINE CELL; BENIGN APOCRINE BREAST LESION; BREAST CYST; BREAST DISEASE; BREAST LESION; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CARCINOMA IN SITU; COPY NUMBER VARIATION; GENE EXPRESSION PROFILING; HETEROZYGOSITY LOSS; HORMONE DETERMINATION; HUMAN; INVASIVE APOCRINE CARCINOMA; INVASIVE CARCINOMA; MALIGNANT APOCRINE BREAST LESION; MICROARRAY ANALYSIS; PAPILLARY APOCRINE CHANGE; PROTEIN EXPRESSION; REVIEW; TRIPLE NEGATIVE BREAST CANCER;

ANDROGEN RECEPTOR ANTAGONISTS; ANIMALS; APOCRINE GLANDS; BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASMS; RECEPTORS, ANDROGEN;

EID: 84856849698     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.213     Document Type: Review

References (51)

1. Mazoujian G, Pinkus GS, Davis S, Haagensen DE Jr. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am. J. Pathol. 110(2), 105-112 (1983). (Pubitemid 13147256)
2. Viacava P, Naccarato AG, Bevilacqua G. Apocrine epithelium of the breast: Does it result from metaplasia? Virchows Arch. 431(3), 205-209 (1997). (Pubitemid 27440365)
3. Selim AG, Wells CA. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: Relation to oestrogen and progesterone receptors. J. Clin. Pathol. 52(11), 838-841 (1999). (Pubitemid 29524947)
4. Tsung JS, Wang TY, Wang SM, Yang PS. Cytological and biochemical studies of breast cyst fluid. Breast 14(1), 37-41 (2005). (Pubitemid 40197825)
5. Dixon JM, McDonald C, Elton RA, Miller WR. Risk of breast cancer in women with palpable breast cysts: A prospective study. Edinburgh Breast Group. Lancet 353(9166), 1742-1745 (1999). (Pubitemid 29240372)
6. Wells CA, El-Ayat GA. Non-operative breast pathology: Apocrine lesions. J. Clin. Pathol. 60(12), 1313-1320 (2007). (Pubitemid 350247246)
7. Page DL, Dupont WD, Jensen RA. Papillary apocrine change of the breast: Associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol. Biomarkers Prev. 5(1), 29-32 (1996).
8. Masood S, Rosa M. Borderline breast lesions: Diagnostic challenges and clinical implications. Adv. Anat. Pathol. 18(3), 190-198 (2011).
9. Kosemehmetoglu K, Guler G. Papillary apocrine metaplasia and columnar cell lesion with atypia: Is there a shared common pathway? Ann. Diagn. Pathol. 14(6), 425-431 (2010).
10. Elayat G, Selim AG, Wells CA. Alterations of the cell cycle regulators cyclin D1, cyclin A, p27, p21, p16, and pRb in apocrine metaplasia of the breast. Breast J. 15(5), 475-482 (2009).
11. O'Malley FP, Bane AL. The spectrum of apocrine lesions of the breast. Adv. Anat. Pathol. 11(1), 1-9 (2004).
12. Masood S, Rosa M. The challenge of apocrine proliferations of the breast: A morphologic approach. Pathol. Res. Pract. 205(3), 155-164 (2009).
13. Seidman JD, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast: A clinicopathologic study of 37 patients with 8.7-year follow-up. Cancer 77(12), 2529-2537 (1996). (Pubitemid 26000009)
14. Visscher DW. Apocrine ductal carcinoma in situ involving a sclerosing lesion with adenosis: Report of a case. Arch. Pathol. Lab. Med. 133(11), 1817-1821 (2009).
15. O'Malley FP, Bane A. An update on apocrine lesions of the breast. Histopathology 52(1), 3-10 (2008). (Pubitemid 350265178)
16. Elayat G, Selim AG, Wells CA. Cell cycle alterations and their relationship to proliferation in apocrine adenosis of the breast. Histopathology 54(3), 348-354 (2009).
17. Selim AG, El-Ayat G, Wells CA. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Virchows Arch. 441(5), 449-455 (2002). (Pubitemid 35430459)
18. Elayat G, Selim AG, Wells CA. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast. Ann. Diagn. Pathol. 14(1), 1-7 (2010).
19. No authors listed. Consensus conference on the classification of ductal carcinoma in situ. Hum. Pathol. 28(11), 1221-1225 (1997).
20. Leal C, Henrique R, Monteiro P et al. Apocrine ductal carcinoma in situ of the breast: Histologic classification and expression of biologic markers. Hum. Pathol. 32(5), 487-493 (2001). .. Established detailed histological criteria for the classification and grading of apocrine ductal carcinoma in situ (ADCIS). An association between high-grade ADCIS and HER2/neu overexpression and a high rate of cell proliferation was also revealed. (Pubitemid 32506518)
21. Tavassoli FA, Devilee P. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. IARC Press, Lyon, France (2003).
22. Eusebi V, Millis RR, Cattani MG, Bussolati G, Azzopardi JG. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am. J. Pathol. 123(3), 532-541 (1986). (Pubitemid 16090148)
23. Honma N, Takubo K, Akiyama F et al. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Histopathology 47(2), 195-201 (2005). (Pubitemid 41113123)
24. Celis JE, Gromova I, Gromov P et al. Molecular pathology of breast apocrine carcinomas: A protein expression signature specific for benign apocrine metaplasia. FEBS Letters 580(12), 2935-2944 (2006). (Pubitemid 43729167)
25. Selim AG, Ryan A, El-Ayat G, Wells CA. Loss of heterozygosity and allelic imbalance in apocrine metaplasia of the breast: Microdissection microsatellite analysis. J. Pathol. 196(3), 287-291 (2002). (Pubitemid 34189417)
26. Lininger RA, Zhuang Z, Man Y, Park WS, Emmert-Buck M, Tavassoli FA. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast. Mod. Pathol. 12(12), 1083-1089 (1999). (Pubitemid 30033539)
27. Washington C, Dalbegue F, Abreo F, Taubenberger JK, Lichy JH. Loss of heterozygosity in fibrocystic change of the breast: Genetic relationship between benign proliferative lesions and associated carcinomas. Am. J. Pathol. 157(1), 323-329 (2000). (Pubitemid 30641748)
28. Jones C, Damiani S, Wells D, Chaggar R, Lakhani SR, Eusebi V. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am. J. Pathol. 158(1), 207-214 (2001). (Pubitemid 32096486)
29. Farmer P, Bonnefoi H, Becette V et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 24(29), 4660-4671 (2005). .. First study that identified a group of breast cancer with increased androgen signaling and a 'molecular apocrine' gene expression profile. (Pubitemid 41032603)
30. Weigelt B, Horlings HM, Kreike B et al. Refinement of breast cancer classification by molecular characterization of histological special types. J. Pathol. 216(2), 141-150 (2008).
31. Guedj M, Marisa L, de Reynies A et al. A refined molecular taxonomy of breast cancer. Oncogene doi:10.1038/onc.2011.301 (2011) (Epub ahead of print). . Presents the most recent and comprehensive molecular taxonomy of breast cancer, in which the molecular apocrine subgroup represents a well-defined clinicobiological entity for breast cancer.
32. Doane AS, Danso M, Lal P et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 25(28), 3994-4008 (2006). (Pubitemid 43990755)
33. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
34. Sorlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98(19), 10869-10874 (2001). (Pubitemid 32878711)
35. Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100(14), 8418-8423 (2003). (Pubitemid 36842560)
36. Ni M, Chen Y, Lim E et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1), 119-131 (2011). .. Provides evidence that drugs targeting the androgen receptor (AR) and AR-regulated signaling cascade are potential therapies for estrogen receptor (ER)-negative breast cancers harboring HER2 overexpression.
37. Teschendorff AE, Naderi A, Barbosa-Morais NL, Caldas C. PACK: Profile analysis using clustering and kurtosis to find molecular classifiers in cancer. Bioinformatics 22(18), 2269-2275 (2006). (Pubitemid 44390883)
38. Sanga S, Broom BM, Cristini V, Edgerton ME. Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family. BMC Medical Genomics 2, 59 (2009).
39. Banneau G, Guedj M, MacGrogan G et al. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations. Breast Cancer Res. 12(4), R63 (2010).
40. Abati AD, Kimmel M, Rosen PP. Apocrine mammary carcinoma. A clinicopathologic study of 72 cases. Am. J. Clin. Pathol. 94(4), 371-377 (1990). (Pubitemid 20316558)
41. d'Amore ES, Terrier-Lacombe MJ, Travagli JP, Friedman S, Contesso G. Invasive apocrine carcinoma of the breast: A long term follow-up study of 34 cases. Breast Cancer Res. Treat. 12(1), 37-44 (1988).
42. Moinfar F, Okcu M, Tsybrovskyy O et al. Androgen receptors frequently are expressed in breast carcinomas: Potential relevance to new therapeutic strategies. Cancer 98(4), 703-711 (2003). (Pubitemid 36959265)
43. Park S, Koo JS, Kim MS et al. Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann. Oncol. 22(8), 1755-1762 (2011).
44. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen receptor expression in breast cancer in relation to molecular phenotype: Results from the Nurses' Health Study. Mod. Pathol. 24(7), 924-931 (2011).
45. Vranic S, Tawfik O, Palazzo J et al. EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast. Mod. Pathol. 23(5), 644-653 (2010). . Showed that pure apocrine carcinomas (AR-positive, ER-negative) have two distinct molecular phenotypes according to the status of the HER2/neu and EGF receptor, which may have important implications for patient selection in treatment.
46. Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: Expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod. Pathol. 23(2), 205-212 (2010). . The first study to convincingly show that AR expression via immunohistochemistry in ER-negative tumors is related to apocrine differentiation.
47. Naderi A, Hughes-Davies L. A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. Neoplasia 10(6), 542-548 (2008). (Pubitemid 351770298)
48. Naderi A, Chia KM, Liu J. Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer. Breast Cancer Res. 13(2), R36 (2011). . Demonstrates in vivo and in vitro synergies between AR and MEK inhibitors in molecular apocrine breast cancer.
49. Chia KM, Liu J, Francis GD, Naderi A. A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer. Neoplasia 13(2), 154-166 (2011).
50. Gucalp A, Traina TA. Triple-negative breast cancer: Role of the androgen receptor. Cancer J. 16(1), 62-65 (2010).
51. Taplin ME. Drug insight: Role of the androgen receptor in the development and progression of prostate cancer. Nat. Clin. Pract. Oncol. 4(4), 236-244 (2007).